Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
AssigneeRamot at Tel-Aviv University Ltd.
InventorsRimona MARGALIT, Dan Peer
Life of this patent
Estimating the term…
Abstract
Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
Claims21
A method for treating an animal suffering from a pathological condition, comprising administering to said animal an effective amount of a bioactive agent encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan having a molecular weight within the range of about 1×105 to about 1×107 daltons, with a lipid consisting of a phosphatidylethanolamine, wherein the ratio of said phosphatidylethanolamine to said at least one glycosaminoglycan is in the range of 1:1 to 20:1 w/w, and wherein the pathological condition is selected from the group consisting of cancer, bacterial infections, fungal infections, viral infections, parasitic infections and prion infections and said bioactive agent is effective for treating the pathological condition.
In a method for treating an indication with a water soluble drug that is effective for treating said indication, the improvement wherein said drug is administered encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan having a molecular weight within the range of about 1×105 to about 1×107 daltons, with a lipid consisting of a phosphatidylethanolamine, wherein the ratio of said phosphatidylethanolamine to said at least one glycosaminoglycan is in the range of 1:1 to 20:1 w/w.
In a method of diagnostic imaging, comprising the steps of administering a diagnostic agent to a patient and imaging said patient, the improvement wherein said diagnostic agent is a water-insoluble lipidated glycosaminoglycan particle encapsulating a marker used in imaging, and the water-insoluble lipidated glycosaminoglycan particle is in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan having a molecular weight within the range of about 1×105 to about 1×107 daltons, with a lipid consisting of a phosphatidylethanolamine, wherein the ratio of said phosphatidylethanolamine to said at least one glycosaminoglycan is in the range of 1:1 to 20:1 w/w.
In a method of gene delivery and short-term expression of nucleic acids for therapeutic purposes comprising administering to an animal in need thereof an effective amount of nucleic acids for therapeutic purposes, the improvement wherein said nucleic acids are formulated so as to be encapsulated in a water-insoluble lipidated glycosaminoglycan particle in the form of a sphere with the glycosaminoglycan portion of the particle forming a shell on the outside and the lipid portion of the particle forming the inside, without the presence of liposome, said particle comprising the reaction product of at least one glycosaminoglycan having a molecular weight within the range of about 1×105 to about 1×107 daltons, with a lipid consisting of a phosphatidylethanolamine, wherein the ratio of said phosphatidylethanolamine to said at least one glycosaminoglycan is in the range of 1:1 to 20:1 w/w.
Dependencies are inferred from the claim text.